Eyemart Express' 10th Annual Stand Up To Cancer Fundraiser Champions Cancer Research
DALLAS, June 30, 2025 /PRNewswire/ — What started as a single fundraiser for cancer research in 153 Eyemart Express stores a decade ago, has become a powerful tradition to fight the disease that will claim the lives of more than 600,000 Americans this year. With the goal of raising more than $1 million, the leading optical retailer is inviting shoppers to join in supporting nonprofit Stand Up To Cancer® (SU2C) and its cutting-edge research efforts by purchasing SU2C frames through Aug. 30.
Now in its 10th year, Eyemart Express' fundraiser for SU2C is now underway, rallying support both in the retailer's brick-and-mortar stores, which today totals 262 nationwide, and online store. For every pair of the 25 dedicated frames in the SU2C collection sold, Eyemart Express and Visual Eyes Eyewear will donate $5, with a minimum guaranteed donation of $30,000. With inspirational names such as 'Brave,' 'Advocate,' and 'Cure,' the unisex frames start at $69.95 and feature an assortment of on-trend colorful plastic styles in square shapes and traditional metal designs.
'Our mission to improve the lives of people and make a difference in the fight against cancer is simple,' say Katy Hanson, Eyemart Express chief marketing and merchandising officer. 'Shopping with us during this time lets you check off your to-do list of updating your prescription lenses or style with new glasses and contributing to the future of cancer research in a meaningful way.'
Eyemart Express' decade of supporting SU2C proves that everyday eyewear purchases can have an extraordinary impact on people's lives.
Visit a local Eyemart Express store or shop online to join SU2C's mission to raise awareness and fund research to detect and treat cancers with the aspiration to cure all patients. Get more information about the nonprofit organization here.
About Eyemart ExpressEyemart Express is more than just a local eye care provider—we are eye care experts embedded in the fabric of our local communities. Doctor-founded in 1990, our team has grown alongside our customers and their families, bringing quality and accessible eye care services to each town we serve. Partnerships with local optometrists, skilled lab specialists, and local labs enable us to deliver glasses in as little as 30 minutes in our 262 stores nationwide. We offer a seamless blend of the latest technology, comprehensive eye care, and genuine human connection to deliver glasses that are 'Made Today, Shipped Tomorrow' anywhere in the United States. Eyemart Express is a VSP Vision™ company that ranks among the top optical retailers in the country with its family of brands: Vision 4 Less, Visionmart Express, and Eyewear Express. For more information about Eyemart Express, visit eyemartexpress.com.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Sun
a day ago
- The Sun
Trump pressures 17 pharma CEOs to cut US drug prices
WASHINGTON: President Donald Trump sent letters to the leaders of 17 major pharmaceutical companies outlining how they should slash U.S. prescription drug prices to match those paid overseas, the White House said on Thursday. Trump signed a sweeping executive order in May demanding drugmakers cut U.S. medicine prices to match those abroad, saying that if companies did not comply, the government could use rulemaking to bring prices down or pursue other measures, such as importing cheaper medicines from overseas. Trump sent the letters to the chief executives of Eli Lilly , Sanofi, Regeneron, Merck & Co , Johnson & Johnson, and AstraZeneca, among others, the White House said. 'Most proposals my Administration has received to 'resolve' this critical issue promised more of the same; shifting blame and requesting policy changes that would result in billions of dollars in handouts to industry,' Trump wrote in the letters, copies of which were posted on his Truth Social account. Shares of Pfizer, Eli Lilly and Gilead Sciences closed down about 2% each, while the NYSE Arca Pharmaceutical Index fell 3% on Thursday. Trump called on drugmakers to provide so-called most-favored-nation prices to every patient enrolled in the government Medicaid health program for low-income people, and to guarantee such pricing for new drugs. The policy is aimed at cutting U.S. prescription drug prices to the lowest possible price paid by members of the Organisation for Economic Co-operation and Development, which includes most of the world's largest economies. Trump also said companies must return excess overseas revenue from raising prices in other countries to offset lower prices in the U.S. to American patients and taxpayers through an agreement with the government. He is requiring drugmakers to stipulate they would not offer other developed nations better prices than what they offer the United States, and said his administration would provide ways to cut out middlemen and sell directly to patients, provided they do so at most-favored-nation prices. Trump gave companies until September 29 to respond with binding commitments to those terms. 'If you refuse to step up, we will deploy every tool in our arsenal to protect Americans from abusive drug pricing practices,' he warned. Analysts, lobbyists and drug pricing experts said it seemed unlikely that the pharmaceutical companies would comply with Trump's demand to lower U.S. prices. 'I might expect them to try to determine if any of their current products might be made available via direct sales (one of the requests) at a lower price than currently available in the U.S.,' said Stacie Dusetzina, professor of health policy at Nashville's Vanderbilt University. UBS analyst Trung Huynh said Trump's letters were a repeat of earlier demands and played down any likely industry impact, calling it 'just another shot in the dark.' Trump has already pushed for voluntary changes and some companies have pledged to build new U.S. manufacturing plants. U.S. patients pay by far the most for prescription medicines, often nearly three times more than in other developed nations. The country also invests heavily in pharmaceutical research and development. Drugmakers have said drastic price cuts would stifle innovation. Pharmaceutical companies including Pfizer, Novartis , AbbVie, and German Merck KGaA's U.S. division, EMD Serono, said they were open to working with the Trump administration. Pfizer is working closely with the Trump Administration and Congress to improve access and affordability for American patients, said spokeswoman Amy Rose. 'Our discussions have been productive,' she said-REUTERS
The Star
a day ago
- The Star
US securities regulator lays out sweeping plans to accommodate crypto
FILE PHOTO: Chairman of the Securities and Exchange Commission (SEC) Paul Atkins looks on during his swearing-in ceremony, at the White House in Washington, D.C., U.S., April 22, 2025. REUTERS/Kevin Lamarque/File photo (Reuters) -The head of the U.S. securities regulator unveiled sweeping plans to overhaul capital markets regulations on Thursday to accommodate cryptocurrencies and blockchain-based trading, in a major win for the digital asset industry, which has long pushed for tailored rules. Securities and Exchange Commission Chair Paul Atkins said in remarks that he has directed commission staff to craft guidelines to determine when a crypto token is a security as well as proposals for a wide range of disclosures and exemptions. Atkins also said he has asked SEC staff to work with firms looking to offer tokenized securities -- blockchain-based shares of stocks or funds. "This represents more than a regulatory shift — it is a generational opportunity," Atkins said in a speech before the America First Policy Institute, a think tank that was created to support President Donald Trump's policy agenda. If enacted, Atkins' proposals would represent a broad shift for U.S. securities regulation, potentially enabling crypto to become more enmeshed with traditional finance. Details of his plans for crypto come just a day after a cryptocurrency working group formed by Trump called on the SEC to create new rules specific to digital assets and outlined the administration's stances on market-defining crypto legislation. In a landmark report, the White House encouraged the SEC and the Commodity Futures Trading Commission to use their existing authorities to "immediately enable the trading of digital assets at the federal level." On the campaign trail last year, Trump courted crypto cash by pledging to be a "crypto president" and promote the adoption of digital assets. That is in stark contrast to former Democratic President Joe Biden's regulators, who, in a bid to protect Americans from fraud and money laundering, cracked down on the industry. The Biden administration's SEC sued exchanges Coinbase, Binance, and dozens more, alleging they were flouting U.S. laws. Trump's SEC has since dropped those cases. (Reporting by Hannah Lang in New York; Editing by Aurora Ellis)
The Star
2 days ago
- The Star
US weekly jobless claims rise marginally
WASHINGTON: The number of Americans filing new applications for unemployment benefits increased marginally last week, suggesting that the labour market remained stable, though it is taking longer for laid-off workers to find new opportunities. Initial claims for state unemployment benefits rose 1,000 to a seasonally adjusted 218,000 for the week ended July 26, the Labor Department said on Thursday. Economists polled by Reuters had forecast 224,000 claims for the latest week. The labor market has slowed, with economists saying uncertainty over where President Donald Trump's tariff levels will eventually settle has left businesses wary of adding headcount. But labor supply has also declined amid the White House's immigration crackdown. The Federal Reserve on Wednesday left its benchmark interest rate in the 4.25%-4.50% range, resisting pressure from President Donald Trump to lower borrowing costs. Fed Chair Jerome Powell told reporters the labor market was in balance. But he added because that was partly due to both demand and supply declining, "we do see downside risk in the labor market." The central bank cut rates three times in 2024, with the last move coming in December. Most economists expect it to resume policy easing in September. Employers' hesitancy to increase hiring means there are fewer jobs for those being laid off. Government data on Tuesday showed there were 1.06 job openings for every unemployed person in June compared to 1.33 in January. The number of people receiving benefits after an initial week of aid, a proxy for hiring, were unchanged at a seasonally adjusted 1.946 million during the week ending July 19, the claims report showed. The claims data has no bearing on July's employment report, due on Friday as it falls outside the survey period. Nonfarm payrolls likely increased by 110,000 jobs last month after rising 147,000 in June, a Reuters survey of economists showed. The unemployment rate is forecast to rise to 4.2% from 4.1% in June. (Reporting By Lucia Mutikani; Editing by Chizu Nomiyama)
